Engineered Liver Platforms for Different Phases of Drug Development.
Engineered Liver Platforms for Different Phases of Drug Development.
复制标题
设计用于药物开发不同阶段的肝平台。
DOI：
10.1016/j.tibtech.2016.08.001
复制
发表时间：
2017-02
影响因子：
17.3
通讯作者：
Khetani SR
中科院分区：
文献类型：
--
作者：
Ware BR;Khetani SR
Drug-induced liver injury (DILI) remains a leading cause of drug withdrawal from human clinical trials or the marketplace. Due to species-specific differences in liver pathways, predicting human-relevant DILI using in vitro human liver models is critical. Microfabrication tools allow precise control over the cellular microenvironment towards stabilizing liver functions for weeks. These tools are used to engineer human liver models with different complexities and throughput using cell lines, primary cells, and stem cell-derived hepatocytes. Including multiple human liver cell types can mimic cell-cell interactions in specific types of DILI. Finally, organ-on-a-chip models demonstrate how drug metabolism in the liver affects multi-organ toxicities. In this review, we survey engineered human liver platforms within the needs of different phases of drug development.
